Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome
Clinical Journal of the American Society of Nephrology · 2025-12 · 20 (12) · 1767-1779
DOI: 10.2215/cjn.0000000842 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 15.10.2025. Verfasst von Cal H Robinson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cure Glomerulopathy, CIHR, Kidney Foundation of Canada.
Abstract (Originalsprache)
Key Points Three quarters of children with steroid-resistant nephrotic syndrome respond to other immunosuppression and have good kidney outcomes. Children classified as frequently relapsing by International Pediatric Nephrology Association versus Kidney Disease Improving Global Outcomes criteria have similar relapse rates and risk of CKD. These findings support defining treatment resistance by response to any immunosuppression and implementing the International Pediatric Nephrology Association criteria for frequent relapses.
Background
In childhood nephrotic syndrome, definitions of immunosuppression response, frequently relapsing nephrotic syndrome (FRNS), and long-term remission are conflicting and based on limited evidence. Our goal was to define treatment response, FRNS, and long-term remission on the basis of associated disease outcomes.
Methods
We included children (6 months–18 years) diagnosed with nephrotic syndrome between 1993 and 2023 in combined Canadian cohorts. We evaluated different definitions of ( 1 ) immunosuppressive treatment response, ( 2 ) FRNS, including Kidney Disease Improving Global Outcomes (KDIGO) 2021 and International Pediatric Nephrology Association (IPNA) 2023 criteria, and ( 3 ) long-term remission. Outcomes were time to CKD, relapse count throughout follow-up, and time to relapse, analyzed by Cox proportional hazards and negative binomial regression.
Results
We included 1114 children with nephrotic syndrome (median age at diagnosis, 3.8 years; 63% male; median follow-up, 4.7 years). Among them, 1054 (95%) were steroid sensitive, 60 (5%) were steroid resistant (steroid-resistant nephrotic syndrome [SRNS]), and 73% with SRNS achieved complete remission with steroid-sparing immunosuppression. No child with treatment-responsive SRNS developed CKD. Within 1 year of diagnosis, 281 steroid-sensitive children (27%) were classified with FRNS by KDIGO and 383 (36%) by IPNA criteria. Children with FRNS by IPNA criteria (versus KDIGO) had a similar number of relapses (adjusted rate ratio, 0.95; 95% confidence interval, 0.81 to 1.12) and CKD risk (2% each) but less often received steroid-sparing immunosuppression (hazard ratio, 0.42; 95% confidence interval, 0.32 to 0.56). Ninety-eight percent of relapses occur within 3 years of the initial diagnosis or the last relapse event.
Conclusions
Children with SRNS who achieve remission have a similar CKD risk to steroid-sensitive children. Children with FRNS by IPNA 2023 and KDIGO 2021 criteria experience similar rates of relapse and CKD. This supports defining treatment resistance by response to any immunosuppressive medication, implementation of the IPNA FRNS criteria, and use of 3-year relapse-free survival as a surrogate for long-term remission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.
- Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Pediatrics, William Osler Health Systems, Brampton, Ontario, Canada.
ORCID-Profile: Cal H Robinson, Tonny H M Banh, Vaneet Dhillon, Mackenzie Garner, Christoph Licht, Ashlene McKay, Seetha Radhakrishnan, Nithiakishna Selvathesan, Chia Wei Teoh, Jovanka Vasilevska-Ristovska, Rulan S Parekh
Förderung
- Cure Glomerulopathy
- CIHR
- Kidney Foundation of Canada
- Physicians' Services Incorporated Foundation
- Hospital for Sick Children
- Canadian Institutes of Health Research
- Women's College Research Institute
- SickKids Clinician-Scientist Training program
Zitieren
APA
Robinson, C. H., Aman, N., Banh, T. H. M., Brooke, J., Dhillon, V., Garner, M., Licht, C., McKay, A., Pearl, R., Radhakrishnan, S., Rasool, K., Selvathesan, N., Teoh, C. W., Vasilevska-Ristovska, J., & Parekh, R. S. (2025). Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology, 20(12), 1767-1779. https://doi.org/10.2215/cjn.0000000842
Vancouver
Robinson CH, Aman N, Banh THM, Brooke J, Dhillon V, Garner M, et al. Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology. 2025;20(12):1767-1779. doi:10.2215/cjn.0000000842
BibTeX
@article{Robinson2025,
author = {Robinson, Cal H and Aman, Nowrin and Banh, Tonny H M and Brooke, Josefina and Dhillon, Vaneet and Garner, Mackenzie and Licht, Christoph and McKay, Ashlene and Pearl, Rachel and Radhakrishnan, Seetha and Rasool, Keisha and Selvathesan, Nithiakishna and Teoh, Chia Wei and Vasilevska-Ristovska, Jovanka and Parekh, Rulan S},
title = {Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {12},
pages = {1767--1779},
doi = {10.2215/cjn.0000000842}
}
EUVIMED